hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06323304 id: 701/HDDD-DHYD briefTitle: Efficacy and Safety of Auricular Acupressure in Treating Allergic Rhinitis overallStatus: RECRUITING date: 2024-03-13 date: 2024-06 date: 2024-06 date: 2024-03-21 date: 2024-04-04 name: University of Medicine and Pharmacy at Ho Chi Minh City class: OTHER briefSummary: Allergic rhinitis (AR) is a global health problem affecting approximately 10% to 40% of the population worldwide, with an increasing trend. It significantly impacts health and quality of life. Current treatments for AR include allergen avoidance, symptom-relieving medications, anti-inflammatory therapy, and allergen-specific immunotherapy. However, many patients still experience uncontrolled symptoms despite these approaches, either as monotherapy or in combination, along with medication side effects such as drowsiness, dry eyes, nasal mucosal damage, and immunosuppression.
Auricular acupressure therapy (AAT) utilizes ear acupoints by applying pressure with ear seeds. The neurobiological mechanisms of AAT on the human body have gained increasing attention in clinical and experimental studies, involving anti-inflammatory, antioxidant, and immunomodulatory effects. Its efficacy has been recognized, becoming a potential alternative therapy for various conditions such as sleep disorders, obesity, and chronic pain. Previous clinical studies have reported the efficacy and safety of AAT in treating AR. However, the primary outcomes of these studies remain inconsistent and lack specific criteria for evaluating AR treatment efficacy.
This study aims to investigate the efficacy and safety of AAT in treating AR based on the ARIA guideline 2019 treatment efficacy criteria. It will provide a basis for applying AAT as a complementary approach in the multimodal treatment of AR. conditions: Itching conditions: Runny Nose conditions: Sneezing conditions: Nasal Congestion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Triple-blind method (Participant, Investigator, Outcome assessor) Participants will be blinded to their randomization assignment, either to the intervention group or the control group. Sham acupressure therapy will be performed at acupoints that have no therapeutic effect on allergic rhinitis, and the procedures will be similar to auricular pressure therapy. Both groups will be treated with fluticasone propionate nasal spray, which is the standard treatment.
The physician who perform auricular acupressure therapy or sham acupressure therapy will be aware of the intervention assignment for each group, but they will not be involved in data analysis or outcome assessment. The data analysts and outcome assessors will be blinded to the treatment assignment. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Auricular acupressure name: Sham acupressure name: Standard treatment measure: The change of nasal and non nasal symptom scores measure: The change of Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score measure: The change of relief medication usage measure: Proportion of intervention-related adverse events sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: University of Medical Center HCMC - Branch no.3 status: RECRUITING city: Ho Chi Minh zip: 700000 country: Vietnam name: Chau Ngoc Le, MD role: CONTACT phone: +84942831722 email: lnchau.ntyhct21@ump.edu.vn name: Minh-Man Pham Bui, MD role: CONTACT phone: +84916080803 email: bpmman@ump.edu.vn lat: 10.82302 lon: 106.62965 hasResults: False
nctId: NCT06323291 id: MCC-23077 briefTitle: Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study overallStatus: RECRUITING date: 2024-04-01 date: 2026-03 date: 2026-03 date: 2024-03-21 date: 2024-04-12 name: H. Lee Moffitt Cancer Center and Research Institute class: OTHER name: Canopy Cancer Collective briefSummary: This Pilot Study will evaluate a 12-week pilot program that offers digital health coaching for individuals with pancreatic cancer and their caregivers. conditions: Pancreatic Cancer studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 20 type: ESTIMATED name: Coaching Sessions measure: Recruitment Rate measure: Participant Acceptance of the Digital Health Coaching Program measure: Participant Ease of Usability of the Digital Health Coaching Program measure: Feasibility of Utilizing the Digital Health Coaching Program sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Moffitt Cancer Center status: RECRUITING city: Tampa state: Florida zip: 33612 country: United States name: Emma Hume role: CONTACT phone: 813-745-6426 email: Emma.Hume@moffitt.org name: Kea Turner, MPH, PhD role: PRINCIPAL_INVESTIGATOR name: Pamela Hodul, MD role: PRINCIPAL_INVESTIGATOR lat: 27.94752 lon: -82.45843 hasResults: False
nctId: NCT06323278 id: PD&REHAB briefTitle: Effectiveness of Cognitive Stimulation Treatment in Patients With Parkinson's Disease overallStatus: RECRUITING date: 2021-12-21 date: 2026-12 date: 2027-12 date: 2024-03-21 date: 2024-03-21 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: The goal of this observational study is to evaluate the relationship between GBA mutation and cognitive stimulation treatment response in patients with Parkinson's disease. The main questions it aim to answer are: • assess whether the GBA mutation is associated with greater or lesser response to cognitive training treatment compared to a control group of PD patients without genetic mutations. • investigate the effect of cognitive stimulation program on behavioural aspects as secondary consequence induced by the possible improvement of cognitive abilities following treatment.
Participants will be undergo to: - a neuropsychological evaluation describing their cognitive profile; - a genetic investigation and finally included in a cognitive stimulation programs according to regular clinical practice. Researchers will compare PD patients with GBA mutation and patients without genetic mutation to evaluate the effectiveness of cognitive stimulation treatment. conditions: Parkinson Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 68 type: ESTIMATED name: Cognitive training measure: Efficacy of the cognitive training on cognitive function in PD patients with GBA mutation compared to a control group of PD patients without genetic mutations. measure: The effect of cognitive training on behavioural aspects in PD patients. measure: The effect of cognitive training on behavioural aspects in PD patients. measure: The effect of cognitive training on behavioural aspects in PD patients. measure: The effect of cognitive training on behavioural aspects in PD patients. measure: The effect of cognitive training on behavioural aspects in PD patients. measure: The effect of cognitive training on behavioural aspects in PD patients. measure: The effect of cognitive training on behavioural aspects in PD patients. measure: The effect of cognitive training on behavioural aspects in PD patients. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico status: RECRUITING city: Milan country: Italy name: Fabiana Ruggiero, MSc in Psychology role: CONTACT phone: +390255033621 email: fabiana.ruggiero@policlinico.mi.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06323265 id: ARL-SCLC-001 briefTitle: A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer overallStatus: RECRUITING date: 2024-03-26 date: 2025-04-01 date: 2026-04-01 date: 2024-03-21 date: 2024-03-27 name: Hebei Medical University Fourth Hospital class: OTHER briefSummary: The purpose of this study is to assess efficacy and safety of patients who receive Adebrelimab combined with chemotherapy±chest radiotherapy as first-line treatment of extensive stage small cell lung cancer in the real world. conditions: Extensive Stage Small Cell Lung Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Adebrelimab + chemotherapy name: ±chest radiotherapy measure: Progression free survival (PFS) measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Duration of Overall Response（DoR） measure: Overall survival (OS) measure: Adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jun Wang status: RECRUITING city: Shijiazhuang state: Hebei country: China name: Jun Wang role: CONTACT phone: 13931182128 email: wangjunzr@163.com lat: 38.04139 lon: 114.47861 hasResults: False
nctId: NCT06323252 id: MastihaOil-HT briefTitle: A Study on the Effects of Mastiha Oil in Adults With Hypertriglyceridemia overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-10-30 date: 2025-10-30 date: 2024-03-21 date: 2024-03-21 name: Harokopio University class: OTHER briefSummary: Mastiha Oil is a 100% natural product of the Mediterranean, extracted from the resin of Mastiha. Its composition is high in bioactive ingredients (such as terpenic acids and polyphenols) which have proven anti-inflammatory, antioxidant, cardioprotective, chemoprotective and antimicrobial properties. The aim of this study is to determine the effect of Mastiha oil in adults with Hypetriglyceridemia. 100 participants will be allocated to two groups, (50 in intervention group and 50 in control group). Mastiha oil will be provided in the form of soft gel capsules to the intervention group, whereas the control group will not consume the capsules. Both groups will receive standard nutritional counselling. The intervention will last 3 months.
The effects of the intervention will be evaluated via clinical and laboratory markers. conditions: Hypertriglyceridemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: MastihaOil name: nutritional counsel measure: Change in blood triglycerides sex: ALL minimumAge: 30 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323239 id: SBRT/LDRT+PD-1+GP for r/mNPC briefTitle: SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2028-04-01 date: 2024-03-21 date: 2024-03-21 name: Sun Yat-sen University class: OTHER briefSummary: This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients. conditions: Nasopharyngeal Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 148 type: ESTIMATED name: SBRT name: Low-dose Radiotherapy (LDRT) name: Toripalimab name: Gemcitabine name: Cisplatin name: IMRT measure: Progression-free survival measure: Overall Survival measure: Objective Response Rate measure: Disease Control Rate measure: Adverse Events measure: QoL sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06323226 id: 2024-312-1 briefTitle: The Impact of Sepsis on Long-term Outcomes in Critical Ill Children With Sepsis overallStatus: RECRUITING date: 2019-01-01 date: 2025-01-01 date: 2025-06-01 date: 2024-03-21 date: 2024-03-21 name: West China Hospital class: OTHER briefSummary: This study is conducted in critically ill children with sepsis with a five years follow-up. We aim to investigate the impact of sepsis on long-term outcomes including growth, neurodevelopment, survival rate, quality of life. conditions: Sepsis conditions: Children, Only studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: Mortality sex: ALL minimumAge: 0 Years maximumAge: 16 Years stdAges: CHILD facility: West China Hospital of Sichuan University status: RECRUITING city: Chendu state: Sichuan country: China name: Ji Yi, Doctor role: CONTACT hasResults: False
nctId: NCT06323213 id: SSGJ-610-BA-III-01 briefTitle: Efficacy and Safety Study of 610 in Patients With Severe Asthma overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-06 date: 2026-09 date: 2024-03-21 date: 2024-03-21 name: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. class: INDUSTRY briefSummary: The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma. conditions: Asthma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 480 type: ESTIMATED name: 610 name: Placebo measure: Annualized rate of severe exacerbation events measure: Time to first severe exacerbation event measure: Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit measure: Change from baseline in ACQ score measure: Change from baseline in ST. GEORGE'S Respiratory Questionnaire(SGRQ) measure: Change in pre-bronchodilator forced expiratory volume (FEV1) measure: Assessment of adverse events (AEs) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323200 id: 202400221B0 briefTitle: Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA acronym: LVA overallStatus: COMPLETED date: 2015-09 date: 2023-03 date: 2023-03 date: 2024-03-21 date: 2024-03-21 name: Chang Gung Memorial Hospital class: OTHER briefSummary: This study aimed to address the impact of lymphedema duration on the quality of lymphatic vessels as well as the outcome after LVA using propensity score matching. conditions: Lymphedema studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 189 type: ACTUAL name: lymphaticovenous anastomosis measure: Volume change after LVA. sex: ALL minimumAge: 20 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323187 id: 4656 briefTitle: Optimization of Cervical Collections in Pregnancy acronym: OCCP overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-02-28 date: 2031-02-28 date: 2024-03-21 date: 2024-03-21 name: Dr. Sascha Drewlo class: OTHER briefSummary: Fetal cells are not easily obtained from pregnant patients; this curtails testing to assess the health of the fetus and the mother. Currently, the only way of diagnosing fetal genetic or chromosomal abnormalities is by invasive techniques, such as chorionic villous sampling (CVS) and amniocentesis performed at 10 to 13 weeks and after 15 weeks of gestation, respectively. Although small, there is a risk for fetal loss with these procedures. Transcervical cell sampling (TCS), similar to a Pap smear, is a platform that meets the requirements for prenatal genetic testing (genetic testing with fetal cells obtained before birth), as well as diagnosis of maternal pregnancy complication, at a very early stage of pregnancy (as early as 5 weeks) and carries low risk for the mother and the developing fetus.
This study will examine cervical fluid collected using various noninvasive methods for TCS in pregnant women. The number of placental cells will be assessed against similarly obtained samples from nonpregnant women of reproductive age who lack cells derived from a placenta. Participating volunteers will provide written informed consent. Only standard medical procedures and approved devices will be used for collection of cervical fluid, minimizing risk to the participants and their fetuses. No test results or other benefits will be available to the participants. conditions: Cervix; Pregnancy conditions: Inherited Genetic Conditions (Diagnosis) conditions: Preeclampsia conditions: Fetal Growth Retardation studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 2600 type: ESTIMATED name: Cervical Sampling measure: Cellular content measure: Cell-free content sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06323148 id: ECTOP-1022 briefTitle: Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-31 date: 2029-03-31 date: 2024-03-21 date: 2024-03-21 name: Fudan University class: OTHER briefSummary: This study plans to conduct ctDNA testing on EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients after radical surgery (R0 resection). Patients with positive ctDNA testing will receive standard treatment according to clinical guidelines, while patients with negative ctDNA testing will be assessed based on comprehensive clinical and pathological characteristics. After receiving or not receiving standard adjuvant chemotherapy, patients will be randomly assigned in a 1:1 ratio to either the observation follow-up group (experimental group) or the osimertinib adjuvant treatment group (control group). The aim is to explore whether observation follow-up for patients with negative ctDNA after surgery has a prognosis non-inferior to osimertinib treatment, and to investigate the disease-free survival rate of EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients with positive ctDNA after surgery receiving osimertinib adjuvant treatment, providing more precise treatment guidance for adjuvant therapy in this specific type of NSCLC patients with EGFR mutation-positive tumors. conditions: Lung Cancer conditions: EGFR Gene Mutation conditions: Minimal Residual Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 226 type: ESTIMATED name: Osimertinib name: No adjuvant therapy measure: The 3-year Disease-Free Survival (DFS) rate between the observation group and the osimertinib treatment group. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323135 id: 2019-725 briefTitle: Nutrition Assessment in Advanced Cancer Patients overallStatus: COMPLETED date: 2019-09-17 date: 2023-09-11 date: 2023-09-11 date: 2024-03-21 date: 2024-03-21 name: West China Hospital class: OTHER briefSummary: The goal of this retrospective observational study is to evaluate the prognostic value of nutrition assessment tool in advanced cancers. We aim to evaluate the clinical utility of nutrition assessment tool in predicting the clinical outcomes of cancer patients, which would help the clinicians to make tailored decision for this population. conditions: Advanced Cancer conditions: Nutrition Aspect of Cancer conditions: Prognostic Cancer Model studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 2115 type: ACTUAL measure: All-cause mortality measure: length of stay in hospital sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West China Hospital, Sichuan Universit city: Chengdu state: Sichuan zip: 610041 country: China lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06323122 id: Plating Techniques 2023 briefTitle: A Comparative Study Between Three Different Plating Techniques in Management of Mandibular Parasymphyseal Fractures. overallStatus: COMPLETED date: 2021-01-01 date: 2023-10-01 date: 2023-12-01 date: 2024-03-21 date: 2024-03-21 name: October 6 University class: OTHER briefSummary: The main goal in management of mandibular fractures is to restore the pre-injury form and function, with the least disability and shortest recovery period. conditions: Mandibular Fractures studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 60 type: ACTUAL name: 2.0 miniplates name: 2.3 high profile miniplates name: 3D miniplates measure: Surgery Time measure: complication measure: fracture stability sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: October 6U city: Cairo zip: 12566 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06323109 id: 2023-1331 id: A196200 type: OTHER domain: UW Madison id: Protocol Version 12/21/23 type: OTHER domain: UW Madison briefTitle: US Imaging for the Assessment of LUTS overallStatus: RECRUITING date: 2023-11-28 date: 2026-01-01 date: 2027-01-01 date: 2024-03-21 date: 2024-03-21 name: University of Wisconsin, Madison class: OTHER name: Wisconsin Partnership Program briefSummary: The purpose of this research is to develop an ultrasound (US) based urodynamics (UDS) evaluation of voiding based on successful magnetic resonance imaging (MRI)-UDS evaluation. Both US and MRI are non-invasive imaging techniques, but US is a more cost-effective and widely available technology. 80 participants will be enrolled and will be on study for up to 2.5 hours (1.5 hour MRI and 1 hour US). conditions: Lower Urinary Tract Symptoms conditions: BPH studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: MRI-UDS; US-UDS; MCUD measure: MRI Urodynamics - Change in Bladder Volume measure: MRI Urodynamics - Change in Urine Velocity measure: MRI Urodynamics - Change in Pressure measure: Bladder outlet obstruction index (BOOI) measure: Bladder contractility index (BOI) measure: International Prostate Symptom Score (IPSS) sex: MALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Wisconsin status: RECRUITING city: Madison state: Wisconsin zip: 53705 country: United States name: Gemma Gliori, MS role: CONTACT email: ggliori@uwhealth.org name: Suzanne Hanson, BS role: CONTACT email: shanson@uwhealth.org name: Alejandro Roldan-Alzate, PhD role: PRINCIPAL_INVESTIGATOR name: Wade Bushman, MD, PhD role: SUB_INVESTIGATOR name: Matt Grimes, MD role: SUB_INVESTIGATOR name: Giuseppe Toia, MD role: SUB_INVESTIGATOR name: Ivan Rosado-Mendez, PhD role: SUB_INVESTIGATOR lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06323096 id: AR13067824 briefTitle: Development of Clinical Decision Support System for Severe Patients With Polytrauma overallStatus: RECRUITING date: 2020-12-01 date: 2024-09-01 date: 2024-12-31 date: 2024-03-21 date: 2024-03-21 name: Semey State Medical University class: OTHER name: Ministry of Science and Higher Education of the Republic of Kazakhstan briefSummary: The goal of this observational study is to develop a Clinical Decision Support System for severe patients with polytrauma. The main questions it aims to answer are:
No intervention is planned for this study. conditions: Polytrauma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 500 type: ESTIMATED measure: Prediction of SIRS measure: Rate of ATC prediction in the 24 h after admission using the developed CDSS. measure: Rate of hemorrage prediction in the 24 h after admission using the developed CDSS. measure: Rate of pneumonia prediction using the developed CDSS. sex: ALL minimumAge: 28 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Emergency Hospital status: RECRUITING city: Semey state: Abai zip: 071400 country: Kazakhstan name: Alexander Prokazyuk, MD role: CONTACT phone: +77071891849 email: prokazyuk.md@yandex.ru lat: 50.42675 lon: 80.26669 hasResults: False